Revenue: As of FY2025 Q1, the actual value is USD 65.7 M.

EPS: As of FY2025 Q1, the actual value is USD 0.01.

Telehealth Segment

• Revenue: $52,456,481 for the three months ended March 31, 2025, compared to $30,841,402 for the same period in 2024.
• Cost of Revenue: $8,136,462 for the three months ended March 31, 2025, compared to $4,194,595 for the same period in 2024.
• Gross Profit: $44,320,019 for the three months ended March 31, 2025, compared to $26,646,807 for the same period in 2024.
• Operating Income: $386,865 for the three months ended March 31, 2025, compared to an operating loss of - $6,619,763 for the same period in 2024.

WorkSimpli Segment

• Revenue: $13,241,275 for the three months ended March 31, 2025, compared to $13,302,862 for the same period in 2024.
• Cost of Revenue: $507,254 for the three months ended March 31, 2025, compared to $405,582 for the same period in 2024.
• Gross Profit: $12,734,021 for the three months ended March 31, 2025, compared to $12,897,280 for the same period in 2024.
• Operating Income: $2,156,059 for the three months ended March 31, 2025, compared to $448,518 for the same period in 2024.

Consolidated Metrics

• Total Revenue: $65,697,756 for the three months ended March 31, 2025, compared to $44,144,264 for the same period in 2024.
• Total Cost of Revenue: $8,643,716 for the three months ended March 31, 2025, compared to $4,600,177 for the same period in 2024.
• Total Gross Profit: $57,054,040 for the three months ended March 31, 2025, compared to $39,544,087 for the same period in 2024.
• Operating Income: $2,542,924 for the three months ended March 31, 2025, compared to an operating loss of - $6,171,245 for the same period in 2024.
• Net Income: $1,916,649 for the three months ended March 31, 2025, compared to a net loss of - $6,648,923 for the same period in 2024.

Cash Flow

• Net Cash Provided by Operating Activities: $3,068,387 for the three months ended March 31, 2025, compared to $5,202,159 for the same period in 2024.
• Net Cash Used in Investing Activities: - $2,867,338 for the three months ended March 31, 2025, compared to - $2,190,265 for the same period in 2024.
• Net Cash Used in Financing Activities: - $812,563 for the three months ended March 31, 2025, compared to - $1,047,690 for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: LifeMD plans to continue strengthening its revenues, reducing losses, and improving operational efficiencies across the business. The company expects to improve its cash burn rate over the next 12 months and maintain positive operating cash flows.
• Non-Core Business: The company is expanding its acceptance of insurance to Medicare beneficiaries for qualifying care, initially available to more than 21 million Medicare Part B beneficiaries in 26 states, with plans to expand access nationwide by the end of the second quarter of 2025.